Shares fell after Novartis lost its appeal in a US district court a generic variant of its the heart failure drug Entresto, a key drug in Divi's CDMO portfolio. Bear Case: The ruling of the US ...
Local Spotlight: Managing high bad cholesterol. High bad cholesterol is a risk factor for a common type of heart disease, yet ...
The firm presented early data for a blood-based approach to screen prostate cancer patients for PSMA, which it believes has ...
Roche’s Evrysdi is the market leader among the drugs for spinal muscular atrophy. Biogen’s Spinraza has struggled, but ...
Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of ...
Novartis’ latest effort to block a generic challenger to blockbuster heart med Entresto has come up short, this time in a ...
Scott Hunter, who joined the company nearly 2 years ago, also had stints with Novartis, Shire, and Bausch + Lomb.
J.P. Morgan analyst Richard Vosser maintained a Hold rating on Novartis AG (NOVN – Research Report) on December 3 and set a price target of ...
Previously, Cleerly collected $223 million in mid-2022 through a round backed by T. Rowe Price Associates and Fidelity ...
AstraZeneca appointed Iskra Reic, PhD, as its new EVP of international. The drugmaker made this personnel move after ...
The company's product is therapeutically equivalent to Novartis Pharmaceuticals Corporation's Votrient tablets (200 mg).